KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Revenue (2016 - 2025)

Historic Revenue for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $1.1 billion.

  • Alnylam Pharmaceuticals' Revenue rose 8494.54% to $1.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.1 billion, marking a year-over-year increase of 4009.82%. This contributed to the annual value of $3.7 billion for FY2025, which is 6519.29% up from last year.
  • As of Q4 2025, Alnylam Pharmaceuticals' Revenue stood at $1.1 billion, which was up 8494.54% from $1.2 billion recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Revenue registered a high of $1.2 billion during Q3 2025, and its lowest value of $30.0 million during Q1 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Revenue value was $327.2 million (recorded in 2022), while the average stood at $455.4 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Revenue surged by 18396.25% in 2023, and later crashed by 9393.12% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Revenue (Quarter) stood at $258.5 million in 2021, then rose by 29.59% to $335.0 million in 2022, then surged by 31.25% to $439.7 million in 2023, then skyrocketed by 34.9% to $593.2 million in 2024, then skyrocketed by 84.95% to $1.1 billion in 2025.
  • Its Revenue stands at $1.1 billion for Q4 2025, versus $1.2 billion for Q3 2025 and $773.7 million for Q2 2025.